By Fineline Cube The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released a revised draft of the Standards for Written Deficiency Communications in Drug Review for public comment, introducing a significant policy shift that eliminates opportunities for supplemental data submission in cases involving major deficiencies.
Regulatory Framework Update
| Item | Detail |
|---|---|
| Agency | Center for Drug Evaluation (CDE), NMPA |
| Document | Standards for Written Deficiency Communications in Drug Review (Revised Draft) |
| Release Date | 24 Jul 2026 |
| Previous Version | Included in Procedures for Supplemental Data Submission (Trial), No. 42 of 2020 (November 2020) |
| Comment Period | Currently open for public feedback |
| Key Change | Elimination of supplemental data requests for major deficiencies |
Key Revisions & Policy Changes
Deficiency Classification Clarity
- Severity Designation: Addresses ambiguous descriptions of defect severity that previously failed to clearly designate deficiencies as “major or minor”
- Major Deficiency Definition: Provides clearer criteria for what constitutes a “major” deficiency in drug applications
- Standardization: Harmonizes deficiency communication language across different review divisions
New “No Supplemental Data” Provision
The most significant change introduces a catch-all provision stating:
“If the Center for Drug Evaluation identifies major deficiencies during the review process, it shall no longer request the applicant to submit supplemental data, and shall render a negative approval decision based on the submitted application materials as already on file.”
This represents a fundamental shift from the previous approach, which allowed applicants multiple opportunities to address deficiencies through supplemental submissions.
Impact on Review Process
- Efficiency Focus: Streamlines the review process by eliminating lengthy back-and-forth communications for fundamentally flawed applications
- Quality Emphasis: Places greater responsibility on applicants to submit complete, high-quality applications initially
- Timeline Predictability: Reduces uncertainty in approval timelines by establishing clear decision points
Industry Implications
For Pharmaceutical Companies
- Higher Stakes: Initial application quality becomes critical, as major deficiencies will result in immediate rejection without opportunity for correction
- Resource Allocation: Companies may need to invest more heavily in pre-submission consultation and internal quality assurance processes
- Strategic Planning: Development programs must ensure comprehensive data packages that anticipate potential regulatory concerns
For Regulatory Strategy
- Pre-Submission Meetings: Increased importance of formal meetings with CDE to clarify requirements and expectations before filing
- Gap Analysis: Enhanced need for thorough gap analysis against current regulatory standards before submission
- Risk Assessment: More rigorous internal risk assessment of potential major deficiency areas
Market Context
This regulatory tightening aligns with China’s broader pharmaceutical regulatory modernization efforts, which have increasingly emphasized international harmonization and efficiency. The change mirrors approaches used by other major regulatory agencies, including the FDA and EMA, which also limit opportunities for addressing major deficiencies post-submission.
Industry analysts estimate that this change could impact 15-20% of drug applications that historically relied on supplemental data submissions to address significant issues identified during review.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory policy changes. The draft standards are subject to public comment and may be modified before final implementation. Actual regulatory outcomes and industry impacts may differ due to policy revisions, stakeholder feedback, and implementation details.-Fineline Info & Tech